Opinion|Videos|January 12, 2026
Emerging Therapies in Schizophrenia
Panelists discuss how emerging therapies targeting new pathways may revolutionize schizophrenia management.
Advertisement
Episodes in this series
Panelists discuss how innovative treatments—including glutamatergic modulators, muscarinic agonists, and digital interventions—represent the next frontier of schizophrenia care.
Panelists discuss how these new agents aim to address cognitive and negative symptoms often resistant to traditional therapy, filling critical gaps in patient outcomes.
Panelists discuss how combining emerging pharmacologic innovations with technology-driven support could transform disease management over the next decade.
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
3
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5